Molecular Partners AG

Research Molecular Partners AG (MOLN) on Bullrun: market cap USD 148.54M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMOLN
• ExchangeNASDAQ
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 148.54M
• Financial periodQ1 2026
• Net income-USD 13.14M
• Free cash flow-USD 48.69M

Valuation Snapshot

latest market cap is USD 148.54M.

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia;

Frequently asked questions

What is Molecular Partners AG's market cap?

Molecular Partners AG's market capitalization is USD 148.54M.

What does Molecular Partners AG do?

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.